Cargando…
Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
Alpha 1 Antitrypsin deficiency (AATD) is a hereditary condition characterized by low serum Alpha 1 Antitrypsin (AAT) levels and a predisposition towards early-onset emphysema. Infusion of AAT is the only disease-modifying therapy that can sufficiently raise plasma AAT levels above the putative prote...
Autores principales: | Herth, Felix J F, Sandhaus, Robert A, Turner, Alice M, Sucena, Maria, Welte, Tobias, Greulich, Timm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570922/ https://www.ncbi.nlm.nih.gov/pubmed/34754184 http://dx.doi.org/10.2147/COPD.S325211 |
Ejemplares similares
-
New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020) -
Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017) -
The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
por: Janciauskiene, Sabina, et al.
Publicado: (2018) -
Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020) -
The Relationship between Plasma Alpha-1-Antitrypsin Polymers and Lung or Liver Function in ZZ Alpha-1-Antitrypsin-Deficient Patients
por: Sark, Annelot D., et al.
Publicado: (2022)